Cytune is a private company developing a broad portfolio of novel immunotherapeutic agents to treat primarily cancer.
Cytune’s hedge relies on a proprietary scientific breakthrough in immunology: effective form of a major human immunocytokine: trans-presentation mechanism of a critical immune factor: IL-15
Cytune’s proprietary most advanced proprietary compound, CYP 0150, is a human interleukin-15 uniquely linked to its effector.
Cytune is further developing conjugated monoclonal antibodies linked to CYP 0150.
Cytune was founded in 2007 and is managed by Dr. David Bechard, a successful serial biotech entrepreneur and Dr. Yannick Jacques, Director of Public Research at the Inserm (National Institute for Health and Medical Research)
Cytune’s technology originally emanates from researches performed at the Inserm unit U892 of Nantes, France.